2021年6月14日,辉瑞全球研发中心的研究人员在国际顶尖医学期刊Nature Medicine在线发表了题为:Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial的临床试验论文。 这项1期临床试验表明,辉瑞公司开发的一种口服的小分子胰高血糖素样肽-1受体(...
Despite years of research in the field of type 1 diabetes, patients with the disease remain without a therapeutic agent that can alter the underlying immune response in a clinically beneficial way. Glucagon-like peptide 1 agonist therapies have shown some promising effects in terms of positively af...
1.Drucker D, Nauck M. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696. 2.Giorgino F, Natalicchio A, Leonardini A, et al. Exploiting the pleiotropic actions of GLP-1 for the management of type ...
概括地讲,这些人源长效GLP-1药物的共同特征是运用基因工程技术使GLP-1类似物与人体的免疫球蛋白IgG(FC片段)或者人体白蛋白(albumin)融合或结合,使其在体内避免快速被肾脏清除和代谢降解,延长半衰期。 杜拉鲁肽为GLP-1与人IgG4-Fc连接的融合蛋白,由将GLP-1类似物的N-末端与经过修饰的人IgG4重链Fc段,通过一个...
图6GIP与GLP-1受体相互作用的潜在机制 GCGR信号通路:GCGR是胰高血糖素受体,主要存在于肝脏,胰高血糖激活GCGR在体内调节肝脏葡萄糖合成和分解代谢,从而维持体内血糖浓度。《Pancreatic alpha cell glucagon–liver FGF21 axis regulates beta cell regeneration in a mouse mod...
idiabetes”关注我们, 然后点右上角“…”菜单,选择“设为星标” 编者按: 自GLP-1被发现以来,它已然成为一种“多面手”激素——一个接一个代谢功能被人们发现,远远超出了其作为肠促胰素的经典定义。GLP-1的众多有益的多靶点作用使其逐渐成为更多新兴的治疗领域如脂肪肝、肥胖和神经退行性疾病等的冉冉之“星”药...
[3] Andreasen CR, Andersen A, Knop FK, Vilsbøll T. Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. Diabetes Obes Metab. 2021 Sep;23 Suppl 3:40-52. ...
1. Quast DR, Nauck MA, Schenker N, Menge BA, Kapitza C, Meier JJ. Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. Diabetes Obes Metab. 2021;23(10):2344-...
【关键词】 糖尿病,2型; 动脉粥样硬化性心血管疾病; 胰高糖素样肽-1受体激动剂 Consensusrecommendationsonutilizingglucagon‑likepeptide‑1(GLP‑1) receptor agonists in the treatment of type 2 diabetes mellitus Chinese Society of Endocrinology, Chinese Diabetes Society Corresponding author: Mu Yiming,...
JAMA子刊:GLP-1类药物,或可大幅降低结直肠癌风险 美国凯斯西储大学医学院的研究人员在 JAMA 子刊 JAMA Oncology 上发表了一篇题为:GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes,With and Without Overweight/Obesity 的研究论文。